Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs POMALIDOMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Multiple myeloma, relapsed or refractory (in combination with dexamethasone),Multiple myeloma, maintenance therapy post-autologous stem cell transplant,AIDS-related Kaposi sarcoma (off-label),Primary effusion lymphoma (off-label)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal half-life approximately 7.5 hours in patients with normal renal function; prolonged to 9-12 hours in moderate renal impairment.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily metabolized by CYP1A2 and CYP3A4; undergoes glucuronidation via UGT1A8.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal (73% as unchanged drug and metabolites), fecal (15%), biliary (minimal).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
12-44% bound to albumin and alpha-1-acid glycoprotein; mean ~30%.
4-6 L/kg; large Vd indicates extensive tissue distribution
62-138 L (approx 0.8-1.7 L/kg); indicates extensive tissue distribution.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 73% (range 56-85%); high fat meal reduces AUC by 13% but no significant effect.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Cr Cl 30-59 m L/min: 3 mg once daily. Cr Cl <30 m L/min: 2 mg once daily. Not recommended if Cr Cl <15 m L/min or requiring dialysis.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh A: 4 mg once daily. Child-Pugh B: 2 mg once daily. Child-Pugh C: 1 mg once daily.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Safety and efficacy not established; no recommended dosing.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment; monitor for increased toxicity (e.g., myelosuppression, neurotoxicity) due to age-related organ function decline.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
WARNING: EMBRYO-FETAL TOXICITY, VENOUS AND ARTERIAL THROMBOEMBOLISM, HEPATOTOXICITY, and INCREASED MORTALITY IN MULTIPLE MYELOMA. Pomalidomide is contraindicated in pregnant women due to teratogenicity. Thromboembolic events (DVT, PE, MI, stroke) are increased. Hepatotoxicity may be severe. In multiple myeloma clinical trials, pomalidomide/dexamethasone was associated with increased mortality in patients with high-risk cytogenetics (del 17p, t(4;14), t(14;16)).
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Embryo-fetal toxicity (must use contraception); venous/arterial thromboembolism (consider prophylaxis); hepatotoxicity (monitor LFTs); increased mortality in high-risk multiple myeloma; hematologic toxicity (neutropenia, thrombocytopenia); cardiac toxicity (arrhythmias, heart failure); severe cutaneous reactions; tumor lysis syndrome; renal impairment; fetal risk during pregnancy; avoid use in patients with prior hypersensitivity to thalidomide analogs.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Pregnancy (absolute); women of childbearing potential not using effective contraception; men not using condoms during sexual activity with pregnant or non-pregnant women; hypersensitivity to pomalidomide or thalidomide analogs; prior severe dermatologic reactions to pomalidomide.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
Avoid grapefruit juice and grapefruit products. Take with water, not with food to reduce nausea.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Risk of fetal harm persists; no safe level established; discontinue if possible.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No data on M/P ratio; excreted in animal milk; potential for serious adverse reactions in infant; breastfeeding contraindicated during therapy and for at least 7 days after last dose.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No specific dose adjustments in pregnancy due to contraindication; pharmacokinetic changes (e.g., increased clearance) theoretically require higher doses if used, but teratogenicity prohibits use; avoid exposure entirely.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Thromboprophylaxis with aspirin or low molecular weight heparin is mandatory due to high VTE risk. Monitor CBC and thyroid function monthly. Contraindicated in pregnancy due to teratogenicity. Pomalidomide requires REMS program enrollment. Dose reduction needed for renal impairment (Cr Cl <45 m L/min).
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Do not become pregnant while taking this drug; use two reliable forms of contraception.,Report any signs of bleeding or bruising, as pomalidomide can cause low platelet counts.,Avoid grapefruit and grapefruit juice as they may increase drug levels.,Take capsules whole, not crushed or chewed, with water.,Do not donate blood during treatment and for 4 weeks after stopping.
No interactions on record
"Dextropropoxyphene, an opioid analgesic, and pomalidomide, an immunomodulatory agent, both pose risks of QT interval prolongation. Co-administration may result in additive QT prolongation, increasing the risk of torsade de pointes, a potentially fatal ventricular arrhythmia. Additionally, dextropropoxyphene may exacerbate the sedative and respiratory depressant effects of pomalidomide, leading to excessive central nervous system depression."
"Concomitant use of pomalidomide and perampanel may result in additive central nervous system (CNS) depression due to their independent sedative properties. Pomalidomide, an immunomodulatory drug, is associated with somnolence and fatigue, while perampanel, an AMPA receptor antagonist, commonly causes dizziness, somnolence, and ataxia. This combination can lead to excessive sedation, impaired cognitive function, and increased risk of falls or accidents, particularly in elderly patients or those with impaired hepatic function."
"The concurrent use of desflurane, a halogenated inhalational anesthetic, with pomalidomide, an immunomodulatory agent, may potentiate the risk of severe hypotension and bradycardia due to additive cardiovascular depression. Desflurane directly depresses myocardial contractility and systemic vascular resistance, while pomalidomide can induce vasodilation and negative chronotropic effects. Clinically, patients may experience profound drops in blood pressure and heart rate, leading to reduced cardiac output and potential end-organ hypoperfusion."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs POMALIDOMIDE, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. POMALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory drug with antineoplastic activity; targets cereblon, leading to ubiquitination and degradation of transcription factors Ikaros (IKZF1) and Aiolos (IKZF3), resulting in direct cytotoxicity and immune modulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and POMALIDOMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of POMALIDOMIDE is: 4 mg orally once daily on days 1-21 of a 28-day cycle, in combination with dexamethasone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and POMALIDOMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. POMALIDOMIDE is classified as Category C. First trimester: High risk of severe birth defects (e.g., limb anomalies, neural tube defects) due to potent teratogenicity; absolutely contraindicated. Second/third trimester: Ris. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.